Please ask us questions!
787-900-5661
info@prmedcenter.com
Please let us know you!

Research Studies

We are continuous working with new lines of treatment that have become the new hope for many patients.

AllBreast3Hepatocellular1Lung4Myeloma2Pulmonary and Critical Care1

Breast

Type of Cancer: Breast Sponsor: Sanofi Phase / Design: Phase 2 Randomized Open label Population: Locally advanced Not amenable to surgery / Radio the OR Metastatic Disease ER (+) &…

Breast

Type of Cancer: Breast Sponsor: Sanofi Phase / Design: Phase 2 Window Study Population: Localized & operable: Stage IIStage III Newly diagnosed, Pre-operative post-menopausal ER(+) & HER-2 (-)

Breast Cancer

Type of Cancer: Breast Cancer Sponsor: Sanofi Phase / Design: A Randomized, Multicenter, Double-blind, Phase 3 Study for the Treatment of Patients with ER (+), HER2 (-) Breast Cancer who…

COVID-19

Type: COVID BI 764198 efficacy and safety in prevention/progression of ARDS and ARDS- related complications secondary to COVID-19 (ACTION ON COVID-19) Sponsor: Boeringher Ingelheim Phase / Design: Population:

Hepatocellular

Type of Cancer: Hepatocellular Sponsor: Merck Phase / Design: Phase 3 Randomized Double-blind Population: Incurable Nonmetastatic HCC No macrovascular invasion. Not amenable to transplant All lesions amenable to TACE in…

Lung

Type of Cancer: NSCLC Sponsor: BMS Phase / Design: Phase 3 Randomized Open label Population: Locally advanced: Stage IIIA, IIIB, or IIIC Unresectable Amenable to Chemoradiotherapy Naïve EGFR mutation (-)

Lung

Type of Cancer: NSCLC Sponsor: Merck Phase / Design: Phase 3 Randomized Open label (Rescue site) Population: Metastatic EGFR mutation (-)  

Lung

Type of Cancer: NSCLC Sponsor: BMS Phase / Design: Phase 3 Randomized Double-blind Population: Resectable Stage II-IIIB Naïve EGFR mutation (-)

Lung

Type of Cancer: Lung Sponsor: Mirati Phase / Design: A Randomized Phase 3 Study of MRTX849 versus Docetaxel Population: Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C…

Myeloma

Type of Cancer: Phase 1-2 trial evaluating anti-TGF agent (SAR439459) or pomalidomide in combination with isatuximab and dexamethasone in relapsed or refractory multiple myeloma (RRMM). Sponsor: Sanofi Phase / Design:…
Menu